Hahnemann Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 19-12-2024
- Paid Up Capital ₹ 0.49 M
as on 19-12-2024
- Company Age 28 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.30 M
as on 19-12-2024
- Revenue -1.02%
(FY 2017)
- Profit -69.44%
(FY 2017)
- Ebitda -23.58%
(FY 2017)
- Net Worth -10.40%
(FY 2017)
- Total Assets -21.29%
(FY 2017)
About Hahnemann Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 0.49 M.
The company currently has active open charges totaling ₹8.30 M.
Pooja Narula, Neeru Narula, and Karan Narula serve as directors at the Company.
- CIN/LLPIN
U24232DL1996PTC080135
- Company No.
080135
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jul 1996
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Hahnemann Pharmaceuticals Private Limited offer?
Hahnemann Pharmaceuticals Private Limited offers a wide range of products and services, including Homeopathic Medicines & Remedies, Homeopathic Drugs, Health Conditions, Heart Care, Homeopathy Medicines, Dilutions.
Who are the key members and board of directors at Hahnemann Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pooja Narula  | Director | 14-Jul-1996 | Current |
| Neeru Narula | Director | 14-Jul-1996 | Current |
| Karan Narula | Additional Director | 02-Sep-2019 | Current |
Financial Performance of Hahnemann Pharmaceuticals.
Hahnemann Pharmaceuticals Private Limited, for the financial year ended 2017, experienced Minor drop in revenue, with a 1.02% decrease. The company also saw a substantial fall in profitability, with a 69.44% decrease in profit. The company's net worth observed a substantial decline by a decrease of 10.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hahnemann Pharmaceuticals?
In 2017, Hahnemann Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 29 Mar 2005 | ₹5.30 M | Open |
The Jammu & Kashmir Bank Ltd. Creation Date: 20 Dec 2002 | ₹1.60 M | Open |
Uco Bank Creation Date: 06 Jan 2000 | ₹0.50 M | Open |
How Many Employees Work at Hahnemann Pharmaceuticals?
Unlock and access historical data on people associated with Hahnemann Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hahnemann Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hahnemann Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
